Fol. Biol. 2011, 57, 133-138
https://doi.org/10.14712/fb2011057040133
Effect of PPAR-γ Agonist Rosiglitazone on Bone Mineral Density and Serum Adipokines in C57BL/6 Male Mice
Crossref Cited-by Linking
- Davidson Melissa A., Mattison Donald R., Azoulay Laurent, Krewski Daniel: Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. Critical Reviews in Toxicology 2018, 48, 52. <https://doi.org/10.1080/10408444.2017.1351420>
- Chandran Manju: Diabetes Drug Effects on the Skeleton. Calcif Tissue Int 2017, 100, 133. <https://doi.org/10.1007/s00223-016-0203-x>
- de Oliveira Katharina Morant H., Garlet Gustavo P., De Rossi Andiara, Barreiros Driely, Queiroz Alexandra M., da Silva Lea Assed Bezerra, Nelson-Filho Paulo, da Silva Raquel Assed Bezerra: Effects of Rosiglitazone on the Outcome of Experimental Periapical Lesions in Mice. Journal of Endodontics 2017, 43, 2061. <https://doi.org/10.1016/j.joen.2017.06.026>
- Kang Ju-Hee, Kwak Hyun Jeong, Choi Hye-Eun, Kim Juyoung, Hong Sangmee, Kim Ok-Hee, Oh Byung Chul, Cheon Hyae Gyeong, Han Weiqing: Involvement of Prolyl Hydroxylase Domain Protein in the Rosiglitazone-Induced Suppression of Osteoblast Differentiation. PLoS ONE 2015, 10, e0139093. <https://doi.org/10.1371/journal.pone.0139093>
- Yu Wei-wei, Xia Qin, Wu Yan, Bu Qiao-yun: Activation of PPAR-\u03b3 inhibits differentiation of rat osteoblasts by reducing expression of connective tissue growth factor. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 2014, 34, 652. <https://doi.org/10.1007/s11596-014-1332-y>
- Schwartz Ann V., Vittinghoff Eric, Margolis Karen L., Scibora Lesley M., Palermo Lisa, Ambrosius Walter T., Hue Trisha F., Ensrud Kristine E.: Intensive Glycemic Control and Thiazolidinedione Use: Effects on Cortical and Trabecular Bone at the Radius and Tibia. Calcif Tissue Int 2013, 92, 477. <https://doi.org/10.1007/s00223-013-9703-0>